Predictive value of the thrombotic risk criteria proposed in the 2023 ESC guidelines for the management of ACS: insights from a large PCI registry.
Alessandro SpiritoDavide CaoSamantha SartoriAshutosh SharmaKenneth F SmithBirgit VogelKarim KamaleldinAnoop N KoshyYihan FengDavid PowerUsman BaberParasuram Melarcode-KrishnamoorthySamin K SharmaAnnapoorna KiniGeorge DangasRoxana MehranPublished in: European heart journal. Cardiovascular pharmacotherapy (2023)
The thrombotic risk criteria of the 2023 ESC guidelines for ACS enable to stratify patients undergoing PCI in categories with an incremental 1-year risk of MACE; however, their overall predictive ability for MACE is modest. Future studies should confirm the value of these criteria to identify patients benefiting from an extended treatment with a second antithrombotic agent.
Keyphrases
- acute coronary syndrome
- patients undergoing
- end stage renal disease
- percutaneous coronary intervention
- atrial fibrillation
- antiplatelet therapy
- coronary artery disease
- acute myocardial infarction
- newly diagnosed
- ejection fraction
- chronic kidney disease
- clinical practice
- st elevation myocardial infarction
- peritoneal dialysis
- prognostic factors
- st segment elevation myocardial infarction
- patient reported outcomes
- left ventricular
- patient reported
- breast cancer risk
- smoking cessation